Physician profile
Thilak Chander
NPI 1760698484
$5,163.05
in general payments reported to CMS, 2019-2025
25 companies · $22.92 in 2025
The $22.92 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $1,848 · 2021: $1,711 · 2022: $229 · 2023: $35.74 · 2024: $51.23 · 2025: $22.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $828.40 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $672.00 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $345.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $343.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $336.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $334.76 | 2019-2022 | |
| Grifols USA, LLC | $305.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $284.46 | 2019-2021 | |
| Pfizer INC. | $268.31 | 2019-2021 | |
| Astellas Pharma US INC | $183.17 | 2019-2021 | |
| Horizon Therapeutics Plc | $152.50 | 2020-2023 | Krystexxa |
| Lilly USA, LLC | $144.82 | 2019-2021 | |
| Esperion Therapeutics, INC. | $108.24 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $102.47 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $84.18 | 2020-2021 | |
| Amgen INC. | $73.57 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.38 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $41.95 | 2021 | |
| Radius Health, INC. | $39.51 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $38.57 | 2020-2021 | |
| Dexcom, INC. | $32.00 | 2020-2021 | |
| Medtronic Minimed, INC. | $18.14 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thilak Chander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.